Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)

First Posted Date: 2013-11-25

Last Posted Date: 2013-11-25

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 48

Registration Number: NCT01992601

Locations: 🇰🇷
Severance Hospital, Yonsei University, Seoul, Korea, Republic of

PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin

Phase 1

Completed

Conditions: Dyslipidemia & Hypertension

Interventions: Drug: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC

First Posted Date: 2013-11-05

Last Posted Date: 2013-11-05

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 185

Registration Number: NCT01975961

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808
Drug: Nexium
Drug: Amoxicillin
Drug: clarithromycin

First Posted Date: 2013-08-13

Last Posted Date: 2013-12-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 95

Registration Number: NCT01921647

Locations: 🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of

Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia

Phase 3

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: YH16410 placebo
Drug: YH16410
Drug: Rosuvastatin
Drug: Telmisartan
Drug: Rosuvastatin placebo
Drug: Telmisartan placebo

First Posted Date: 2013-08-02

Last Posted Date: 2014-07-08

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 210

Registration Number: NCT01914432

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808
Drug: Diclofenac
Drug: YH4808+Diclofenac

First Posted Date: 2013-06-12

Last Posted Date: 2014-01-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 49

Registration Number: NCT01876615

Locations: 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: YH12852
Drug: Prucalopride

First Posted Date: 2013-06-06

Last Posted Date: 2015-05-08

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 127

Registration Number: NCT01870674

Locations: 🇰🇷
Inje Busan Paik hospital, Busan, Korea, Republic of

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

Phase 4

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Anplag(Sarpogrelate)
Drug: Placebo

First Posted Date: 2013-06-05

Last Posted Date: 2021-04-23

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 151

Registration Number: NCT01869881

Locations: 🇰🇷
Korea University, Anam, Seoul, Korea, Republic of

AME Study of [14C]-YH4808 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-YH4808 200 mg

First Posted Date: 2013-04-08

Last Posted Date: 2014-07-14

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 8

Registration Number: NCT01825707

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

YH4808 Postprandial PK/PD Study in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808

First Posted Date: 2013-01-04

Last Posted Date: 2014-04-15

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 21

Registration Number: NCT01761513

Locations: 🇰🇷
Yonsei University Health System(Severance Hospital), Seoul, Seodaemun-gu,Sinchon-dong, Korea, Republic of

Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)

Phase 2

Completed

Conditions: Non-erosive Reflux Disease

Interventions: Drug: YH1885L(Revaprazan)
Drug: Esomeprazole 20mg
Drug: placebo

First Posted Date: 2012-12-17

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 149

Registration Number: NCT01750437

Locations: 🇰🇷
DongA university hospital, Busan, Korea, Republic of
🇰🇷
Catholic Incheon hospital, Incheon, Korea, Republic of
🇰🇷
Kyungbook University hospital, Daegu, Korea, Republic of

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy